• 

Patent Opposition Case Studies From Ipo Records.

📌 Patent Opposition Case Studies 

In India, patent oppositions are conducted under:

Section 25(1) — Pre‑grant opposition (before the patent is granted)

Section 25(2) — Post‑grant opposition (within 12 months after grant)

Opposition grounds include:

Anticipation / lack of novelty

Lack of inventive step

Non‑statutory subject matter (including section 3(d) in pharma)

Insufficient disclosure

Wrong priority claim

Law & order / public interest grounds

⭐ 1. Novartis AG – Gleevec (Imatinib Mesylate) — Pre‑Grant Opposition

Facts

Novartis filed a patent for the beta crystalline form of imatinib mesylate, an important cancer drug. Multiple parties including NGOs and generic companies filed pre‑grant oppositions. They challenged:

Novelty and lack of inventive step

Improper enhancement over known compounds

Non‑patentability under section 3(d) (incremental modifications without improved therapeutic efficacy)

Controller Decision

The patent office rejected the patent application. The controller held that the claimed crystalline form was not novel and lacked inventive step over prior art, and did not show enhanced therapeutic efficacy.

Legal Principle

• Section 3(d) was significantly applied — a higher standard for pharmaceutical derivative claims.
• The pre‑grant opposition successfully demonstrated that merely isolating/specific forms of known drugs without enhanced efficacy cannot be patented.

⭐ 2. Novartis – Defracirox Dispersible Tablets (Pre‑Grant Opposition)

Facts

Novartis sought a patent for a new formulation — dispersible tablets of defracirox. Cipla and others opposed on:

Anticipation by prior disclosures

Lack of inventive step

Lack of technical advancement

Controller Decision

After the opposition process, the controller refused the application for lack of novelty and inventive step, finding that all elements of the claimed formulation were disclosed in earlier publications and common practice.

Legal Principle

• Pre‑grant opposition can succeed purely on novelty/inventive step grounds, even if not involving section 3(d).
• Demonstrates how competitors use the opposition route to prevent broad or weak patents.

⭐ 3. Valganciclovir (Valcyte) — Multiple Oppositions

Facts

A patent application for valganciclovir (a prodrug of ganciclovir) was opposed by NGOs and generic firms. The opponents argued:

The invention was obvious in view of known compounds.

No new technical advance beyond ganciclovir.

Proceedings

The case went through:

Pre‑grant opposition

Controller hearings

Post‑grant challenges after the patent was initially granted

Ultimately, the patent was revoked for lack of inventive step, as the modification from the parent compound to valganciclovir was considered a predictable chemical change.

Legal Principle

• Even after grant, a patent can be invalidated if opponents prove obviousness / lack of inventive step.
• Opposition can be used in multiple stages.

⭐ 4. Zykadia (Ceritinib) — Post‑Grant Opposition

Facts

A leading oncology drug, ceritinib, was patented and subsequently challenged by a generic company through a post‑grant opposition. Grounds included:

Anticipation

Obviousness

Lack of inventive step

Controller Decision

The controller found the patent claims invalid due to lack of novelty and inventive step, after comparing claimed features with prior art submitted by the opponent.

Legal Principle

• Post‑grant opposition is a powerful tool for challenging weak patents even after grant.
• Successful oppositions can pave the way for generics to enter the market sooner.

⭐ 5. Neon Laboratories v. Controller (Procedural Issue in Pre‑Grant Opposition)

Facts

Neon Labs filed a pre‑grant opposition. The controller granted the patent without giving Neon a formal hearing, despite the opponent’s request.

Court Decision

The High Court held the grant was invalid because the opponent was entitled to a hearing under principles of natural justice. The patent office was directed to reconsider opposition with a hearing.

Legal Principle

• Procedural fairness is essential in opposition proceedings.
• If an opponent requests a hearing, the controller must provide that opportunity before grant or refusal.

⭐ 6. Bombay High Court Clarification — Solanke v. Controller

Facts

An inventor’s patent application was refused after pre‑grant opposition findings were merged with examination findings. The applicant challenged the refusal.

Court Decision

The High Court upheld the refusal, clarifying that the controller can logically integrate opposition findings with examination results to reach a valid refusal order.

Legal Principle

• The controller need not treat opposition and examination as totally separate; both can inform the patentability outcome.
• Strengthens the coherence between examination and opposition.

⭐ 7. Lenzing AG v. Grasim (Non‑Pharma Pre‑Grant Opposition)

Facts

Grasim opposed a patent filed by Lenzing for a textile fiber manufacturing process. Opponent alleged:

Prior publication

Lack of inventive step

Insufficiency

Controller Decision

After hearing, the controller rejected the opposition and granted the patent, finding the opponent failed to prove prior art anticipation or obviousness.

Legal Principle

• Not all oppositions succeed — they must be supported by convincing evidence of anticipation or lack of inventive step.
• Shows the opposition mechanism is fair to both challenger and applicant.

📌 Key Legal Takeaways From These Cases

1. Opposition Is a Powerful Tool

Both pre‑grant and post‑grant oppositions can:

Prevent weak patents

Save competitors from long litigation later

Protect public interest by keeping overly broad patents at bay

2. Procedural Fairness Matters

Controllers must:

Give hearings when requested

Examine opposition evidence impartially

3. Pharma Cases Stress Substantive Criteria

Especially in pharmaceutical patents:

Section 3(d) is heavily tested for derivative inventions

Mere structural changes without efficacy enhancement are rejected

Obvious modifications are unpatentable even if isolated successfully

4. Opposition Can Be Strategic

Generic manufacturers often use opposition to:

Delay rivals

Clear the way for generic entry

Challenge high‑value drug patents

🧠 Exam / Research Summary

RELATED Blog

Software Patenting

OpenAI Sued by Multiple Copyright Lawsuits in Indi...

Delhi High Court Rules in Favor of Svamaan in Trad...

US Supreme Court to Decide Whether AI-Generated Ar...

Intellectual Property Laws at Afghanistan

Intellectual Property Laws at Albania

Intellectual Property Laws at American Samoa (US)

Intellectual Property Laws at Angola

Intellectual Property Laws at Antigua and Barbuda

Intellectual Property Laws at Armenia